Herve Hoppenot - Incyte Chairman

INCY Stock  USD 70.39  0.66  0.93%   

Chairman

Mr. Herve Hoppenot is Chairman of the Board, President, Chief Executive Officer of Incyte Corporationrationration. Mr. Hoppenot joined Incyte as President and Chief Executive Officer and a Director in January 2014, and was appointed Chairman of the Board in May 2015 since 2015.
Age 64
Tenure 9 years
Address 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
Phone302 498 6700
Webhttps://www.incyte.com
Hoppenot served as the President of Novartis Oncology, Novartis Pharmaceuticals Corporationrationrationration, the U.S. subsidiary of Novartis AG, a pharmaceutical company, from January 2010 to January 2014. Prior to that, Mr. Hoppenot served in other executive positions at Novartis Pharmaceuticals Corporationrationrationration, serving from September 2006 to January 2010 as Executive Vice President, Chief Commercial Officer of Novartis Oncology and Head of Global Product Strategy & Scientific Development of Novartis Pharmaceuticals Corporationration and from 2003 to September 2006 as Senior Vice President, Head of Global Marketing of Novartis Oncology. Prior to joining Novartis, Mr. Hoppenot served in various increasingly senior roles at Aventis S.A., a pharmaceutical company, including as Vice President Oncology US of Aventis Pharmaceuticals, Inc. from 2000 to 2003 and Vice President US Oncology Operations of Rhone Poulenc Rorer Pharmaceuticals, Inc. from 1998 to 2000.

Incyte Management Efficiency

Return On Tangible Assets is likely to rise to 0.1 in 2024. Return On Capital Employed is likely to rise to 0.12 in 2024. At this time, Incyte's Return On Assets are fairly stable compared to the past year. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities.
Incyte currently holds 38.29 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Incyte has a current ratio of 3.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Incyte's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 5 records

CHAIRMAN Age

Herriot MDAxsome Therapeutics
56
John CrowleyAmicus Therapeutics
57
Stanley CrookeIonis Pharmaceuticals
79
Xiaodong WangBeiGene
61
John OylerBeiGene
56
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Incyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2094 people. Incyte (INCY) is traded on NASDAQ Exchange in USA. It is located in 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 and employs 2,524 people. Incyte is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Incyte Leadership Team

Elected by the shareholders, the Incyte's board of directors comprises two types of representatives: Incyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Incyte. The board's role is to monitor Incyte's management team and ensure that shareholders' interests are well served. Incyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Incyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Tray, Chief Finance
Pamela Murphy, Vice Communications
Sheila JD, General VP
Paula Swain, Executive Resources
Christine Chiou, Head Relations
Michael Morrissey, Executive Operations
PharmD MBA, Executive America
Herve Hoppenot, Chairman, CEO and President and Member of Non-Management Stock Option Committee
Dashyant Dhanak, Executive Vice President Chief Scientific Officer
Steven MD, Executive Officer
Christiana MBA, Executive CFO
Maria JD, Gen VP
MBA MBA, Ex America
Ben Strain, Head Relations
Sheila Denton, Executive Counsel

Incyte Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Incyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Incyte Stock Analysis

When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.